What Happened? Shares of healthcare tech company Omnicell NASDAQ:OMCLfell 9.9% in the afternoon session after the company issued weak guidance for the upcoming quarter that overshadowed its strong second-quarter results.The healthcare technology company reported second-quarter revenue of $312.2 mil…
Q2 2026 results exceeded expectations with strong revenue, profitability, and cash flow, driven by robust demand for Titan XT and OmniSphere. Guidance for bookings was widened due to timing uncertainty, but customer engagement and pipeline remain strong.Based on Omnicell, Inc. [OMCL] Q2 2026 Audio…
Q2 2026 saw 7% revenue growth, significant margin expansion, and strong cash flow, driven by demand for connected devices and SaaS. Full-year guidance was raised for non-GAAP EBITDA and EPS, with leadership changes to support long-term growth.Original document: Omnicell, Inc. [OMCL] SEC 8-K Current…
Q2 2026 saw 7% revenue growth to $312M, with non-GAAP EBITDA up 75% and EPS up 109% year-over-year. Recurring revenue comprised 52% of total, and full-year guidance projects continued growth driven by automation and SaaS expansion.Original document: Omnicell, Inc. [OMCL] Slides Release — Jul. 30 20…
Omnicell reported second-quarter 2026 results with total revenue of $312.2 million and GAAP net income of $24.3 million. The company posted non-GAAP net income per diluted share of $0.94 and non-GAAP EBITDA of $67.2 million for the quarter. Omnicell updated full-year 2026 guidance, raising non-GAAP…
Healthcare tech company Omnicell NASDAQ:OMCLwill be announcing earnings results this Thursday morning. Here’s what investors should know.Omnicell beat analysts’ revenue expectations last quarter, reporting revenues of $309.9 million, up 14.9% year on year. It was an exceptional quarter for the comp…
